9966 — Alphamab Oncology Share News
0.000.00%
Last trade - 00:00- HK$5.54bn
- HK$4.18bn
- CNY566.24m
Brief: Alphamab Oncology Says IND Application For JSKN027 Accepted By CDE, NMPA China
Brief: Alphamab Oncology To Repurchase Shares Up To HK$30 Million
Brief: Alphamab Oncology Says JSKN003 Granted Fast Track Designation By U.S. FDA
Brief: Alphamab Oncology says Jskn003 Granted Breakthrough Therapy Designation For Her2+ Advanced CRC
Brief: Alphamab Oncology To Repurchase Shares Up To HK$20 Million
Alphamab hits 22-month peak as regulator accepts cancer drug application
Brief: Alphamab Oncology Says NDA For KN026 Accepted By NMPA
Brief: Alphamab Oncology Expects HY Profit Of At Least RMB20 Million
Brief: Alphamab Oncology Says Jiangsu Alphamab Engages With Suzhou Alphamab For Tech Development
Brief: Alphamab Oncology's JSKN003 Receives FDA Approval
Alphamab at 20-month high after FDA support for cancer drug
Brief: Alphamab Oncology Says Jskn003 Granted Orphan Drug Designation By U.S. FDA
Brief: Alphamab Oncology Says From July 14-16 Directors And Senior Management Bought 900,000 Shares
Alphamab Oncology drops most in three weeks as majority shareholder cuts stake
Brief: Alphamab Oncology Says Rubymab To Place 14.6 Mln Shares
China Literature drops on removal from Hang Seng Tech Index; Midea, ZTO up
Alphamab Oncology leads slide in HK pharma stocks on Trump's plan to trim medicine prices
Brief: Alphamab Oncology Says Jskn003 Granted Therapy Designation By NMPA
HK-listed Alphamab Oncology jumps on expectation of first annual profit